DE69636907D1 - Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose - Google Patents
Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atheroskleroseInfo
- Publication number
- DE69636907D1 DE69636907D1 DE69636907T DE69636907T DE69636907D1 DE 69636907 D1 DE69636907 D1 DE 69636907D1 DE 69636907 T DE69636907 T DE 69636907T DE 69636907 T DE69636907 T DE 69636907T DE 69636907 D1 DE69636907 D1 DE 69636907D1
- Authority
- DE
- Germany
- Prior art keywords
- cholesterol
- atherosclerosis
- lezithine
- azetyl
- transferase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 4
- 201000001320 Atherosclerosis Diseases 0.000 title abstract 2
- 235000012000 cholesterol Nutrition 0.000 title abstract 2
- 102000004357 Transferases Human genes 0.000 title 1
- 108090000992 Transferases Proteins 0.000 title 1
- 101001130226 Homo sapiens Phosphatidylcholine-sterol acyltransferase Proteins 0.000 abstract 2
- 102100031538 Phosphatidylcholine-sterol acyltransferase Human genes 0.000 abstract 2
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/107—Rabbit
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Confectionery (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US640095P | 1995-11-09 | 1995-11-09 | |
US6400P | 1995-11-09 | ||
PCT/US1996/018159 WO1997017434A2 (en) | 1995-11-09 | 1996-11-08 | The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69636907D1 true DE69636907D1 (de) | 2007-03-29 |
DE69636907T2 DE69636907T2 (de) | 2007-11-22 |
Family
ID=21720680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69636907T Expired - Lifetime DE69636907T2 (de) | 1995-11-09 | 1996-11-08 | Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose |
Country Status (8)
Country | Link |
---|---|
US (1) | US6635614B1 (de) |
EP (1) | EP0871713B1 (de) |
AT (1) | ATE353957T1 (de) |
AU (1) | AU728257B2 (de) |
CA (1) | CA2236982C (de) |
DE (1) | DE69636907T2 (de) |
ES (1) | ES2283007T3 (de) |
WO (1) | WO1997017434A2 (de) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69836626T2 (de) | 1997-04-11 | 2007-04-05 | Takeda Pharmaceutical Co. Ltd. | Proteine mit lecithin-cholesterin acetyltransferase-ähnlicher aktivität, deren herstellung und verwendung |
AU5931600A (en) * | 1999-07-14 | 2001-02-05 | Betagene, Inc. | Lcat recombinant cell line compositions and methods |
WO2003040369A2 (fr) * | 2001-09-17 | 2003-05-15 | Molecular Engines Laboratories | Sequences impliquees dans les phenomenes de suppression tumorale, reversion tumorale, apoptose et/ou resistance aux virus et leur utilisation comme medicaments |
WO2003062416A1 (fr) * | 2002-01-21 | 2003-07-31 | Takeda Chemical Industries, Ltd. | Procede de criblage d'agents preventifs et de remedes pour l'arteriosclerose |
SE0201581D0 (sv) | 2002-05-29 | 2002-05-29 | Scandinavian Biotechnology Res | New improved acyltransferase |
CA2787343C (en) * | 2006-06-26 | 2016-08-02 | Amgen Inc. | Compositions comprising modified lcat and uses thereof |
KR20100040937A (ko) | 2007-07-26 | 2010-04-21 | 암젠 인크 | 변형된 레시틴-콜레스테롤 아실트랜스퍼라제 효소 |
MY198422A (en) | 2009-04-29 | 2023-08-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
ES2552654T3 (es) * | 2009-06-12 | 2015-12-01 | Medimmune, Llc | Uso de LCAT para tratar la anemia y la disfunción de los glóbulos rojos |
WO2013086443A1 (en) | 2011-12-08 | 2013-06-13 | Amgen Inc. | Agonistic human lcat antigen binding proteins and their use in therapy |
US10495652B1 (en) * | 2012-04-13 | 2019-12-03 | Roar Holding Llc | Determination of LCAT |
AU2018362603A1 (en) * | 2017-11-07 | 2020-06-18 | Alphacore Pharma Llc | Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0239631A4 (de) | 1985-10-04 | 1989-01-12 | Biotech Res Partners Ltd | Rekombinante apolipoproteine und verfahren. |
US4943527A (en) * | 1985-10-04 | 1990-07-24 | California Biotechnology Inc. | Mature apoai protein production under serum free culturing conditions |
US5049488A (en) | 1985-11-08 | 1991-09-17 | Genentech, Inc. | Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase |
DE4128288A1 (de) | 1991-08-27 | 1993-03-04 | Boehringer Ingelheim Kg | Verwendung von paf-antagonisten zur behandlung und diagnose von cholestase und anderen krankheiten, die durch einen erhoehten lipoprotein-x spiegel gekennzeichnet sind |
WO1993025581A1 (en) * | 1992-06-12 | 1993-12-23 | N.V. Innogenetics S.A. | New peptides and proteins, process for their preparation and their use as cholesterol acceptors |
SE9203753D0 (sv) * | 1992-12-11 | 1992-12-11 | Kabi Pharmacia Ab | Expression system for producing apolipoprotein ai-m |
FR2718329B1 (fr) | 1994-03-21 | 2002-09-20 | Rhone Poulenc Rorer Sa | Lapin transgénique sensibilisé aux dyslipoprotéinémies. |
FR2731710B1 (fr) | 1995-03-14 | 1997-04-30 | Rhone Poulenc Rorer Sa | Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique |
-
1996
- 1996-11-08 CA CA2236982A patent/CA2236982C/en not_active Expired - Lifetime
- 1996-11-08 DE DE69636907T patent/DE69636907T2/de not_active Expired - Lifetime
- 1996-11-08 AT AT96940403T patent/ATE353957T1/de not_active IP Right Cessation
- 1996-11-08 AU AU77293/96A patent/AU728257B2/en not_active Expired
- 1996-11-08 WO PCT/US1996/018159 patent/WO1997017434A2/en active IP Right Grant
- 1996-11-08 ES ES96940403T patent/ES2283007T3/es not_active Expired - Lifetime
- 1996-11-08 EP EP96940403A patent/EP0871713B1/de not_active Expired - Lifetime
- 1996-11-08 US US09/068,386 patent/US6635614B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2236982C (en) | 2010-07-27 |
WO1997017434A2 (en) | 1997-05-15 |
DE69636907T2 (de) | 2007-11-22 |
EP0871713B1 (de) | 2007-02-14 |
WO1997017434A3 (en) | 1997-06-19 |
CA2236982A1 (en) | 1997-05-15 |
US6635614B1 (en) | 2003-10-21 |
AU728257B2 (en) | 2001-01-04 |
EP0871713A2 (de) | 1998-10-21 |
AU7729396A (en) | 1997-05-29 |
ATE353957T1 (de) | 2007-03-15 |
ES2283007T3 (es) | 2007-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
DE69616333D1 (de) | Thip zur behandlung von schlafstörungen | |
DE59608738D1 (de) | Verwendung von epinastin für die behandlung von schmerzen | |
DE69636907D1 (de) | Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose | |
BG103190A (en) | Substituted pyrimidine derivatives and their pharmaceutical application | |
PT841928E (pt) | Formulacao de libertacao prolongada de d-trep-metilfenidato | |
DE69805973D1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase | |
DE69625691T2 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
PT966447E (pt) | Moleculas pequenas uteis no tratamento de doencas inflamatorias | |
ATE308327T1 (de) | Verwendung von 2-hydroxy-5-phenylazobenzoesäure- derivaten als wirkstoffe zur chemoprävention und chemotherapie von kolonkrebs | |
DE69634951D1 (de) | Topische verwendung von betulinsäure zur behandlung bösartiger melanome | |
DE69835823D1 (de) | Verfahren zur behandlung von patienten die unter multipler sklerose leiden mit konsensus-interferon | |
DE68913667D1 (de) | Imidazole für die Behandlung von Atherosclerose. | |
DE69526437T2 (de) | Transdermal verabreichbare zubereitung zur behandlung von störungen des harnlassens | |
DE69535264D1 (de) | Verfahren zur behandlung von diabetes mittels kgf | |
HUP9800731A2 (hu) | Eljárás ivarsejt osztódás stimulálására | |
ATE271865T1 (de) | Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen | |
DE69638281D1 (de) | Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen | |
TR199902192T2 (xx) | Anti-CDL40 bile�iklerinin tedavi ama�l� uygulama y�ntemleri | |
DE3687097D1 (de) | Therapeutisches mittel zur behandlung haematopoietischer krankheiten. | |
ATE202552T1 (de) | Benzamide für behandlung von neurodegenerativen störungen | |
PT1231908E (pt) | Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia | |
DE69627298D1 (de) | Verwendung von sklareolide für die behandlung von excessiven zellwachstumskrankheiten | |
DE68903930T2 (de) | Lipidemulsion zur behandlung von aids. | |
DE68908445D1 (de) | Mittel zur behandlung von lebererkrankungen. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |